Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm

NCT01638507 is registered in ClinicalTrials.gov with Medtronic Vascular as lead sponsor.

NCT NCT01638507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01638507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
Lead sponsor
Medtronic Vascular
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2012
Completion date
June 30, 2015
Enrollment
230 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease